— UPDATED FRIDAY, MARCH 13, 2020 — If you’re living with multiple sclerosis, COVID-19 and any other rapidly-spreading illness is a reason to be cautious, and to follow guidelines and…
Read More
The Rocky Mountain MS Center’s King Adult Day Enrichment Program (KADEP) continues to offer a diverse variety of outings and adventure recreation opportunities for clients. These trips and outings provide…
Colorado typically returns more than $1 billion in refunds to state taxpayers anually. Now, Coloradans who receive a state income tax refund will have a chance to donate all or…
Today, we’re asking you to support the Rocky Mountain MS Center’s impact on the lives of patients and their families living with MS. Since 1978, the patient’s voice has driven…
Do you need your home to adapt to you? Grab bars, a ramp, or wider doorways are just some examples of home modifications that could save you $5,000 on your Colorado…
The annual open enrollment period for insurance plans is underway from November 1st until December 15th. It is very important to review your health insurance plan before you renew. There are changes…
An initial lab study has shown metformin, a common diabetes drug, can repair nerve damage caused by MS; Researchers plan to conduct human trial next year. Recently, results from animal…
Dr. John Corboy, Co-Director of the Rocky Mountain MS Center at University of Colorado, has been named the inaugural Charles Elliot Morris Chair in Neurology. Dr. Corboy serves as Co-Director…
A recently adopted state law allows for the expanded use of home-based telehealth services in Colorado. Our partners at the Rocky Mountain MS Center at University of Colorado are in…
The US Food and Drug Administration (FDA) has approved oral cladribine (brand named Mavenclad®, EMD Serono) for the treatment of adults with relapsing forms of MS, including relapsing-remitting MS and…